![]() |
![]() |
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
(51) | INT.CL. | C07D 401/04 | (2006.01) |
C07D 401/04 | (2013.01) | ||
A61P 27/02 | (2018.01) | ||
A61P 29/00 | (2018.01) | ||
A61P 31/12 | (2018.01) | ||
A61P 37/00 | (2018.01) | ||
A61P 37/06 | (2018.01) |
(11) | Patento numeris | 3466942 |
(13) | Dokumento rūšis | T |
(96) | Europos patento paraiškos numeris | 18206764.5 |
Europos patento paraiškos padavimo data | 2013-08-08 | |
(97) | Europos patento paraiškos paskelbimo data | 2019-04-10 |
(45) | Paskelbimo apie Europos patento išdavimą data | 2022-04-20 |
(46) | Apibrėžties vertimo paskelbimo data |
(30) | Numeris | Data | Šalis |
201261681477 P | 2012-08-09 | US |
(72) |
TRAVERSE, John Fitzgerald , US
ZHANG, Chengmin , US
FEIGELSON, Gregg B. , US
COHEN, Benjamin M. , US
LEONG, William Wei-Hwa , US
|
(73) |
Celgene Corporation ,
86 Morris Avenue, Summit, NJ 07901,
US
|
(54) | PROCESSES FOR THE PREPARATION OF (S)-3-4-((4-(MORPHOLINOMETHYL) BENZYL)OXY)-1-OXOISOINDOLIN-2-YL) PIPERIDINE-2,6-DIONE AND PHARMACEUTICALLY ACCEPTABLE FORMS THEREOF |
PROCESSES FOR THE PREPARATION OF (S)-3-4-((4-(MORPHOLINOMETHYL) BENZYL)OXY)-1-OXOISOINDOLIN-2-YL) PIPERIDINE-2,6-DIONE AND PHARMACEUTICALLY ACCEPTABLE FORMS THEREOF |